Betamethasone dipropionate/calcipotriol - MC2 Therapeutics

Drug Profile

Betamethasone dipropionate/calcipotriol - MC2 Therapeutics

Alternative Names: BDP/calcipotriene - MC2 Biotek; Calcipotriol/betamethasone dipropionate - MC2 Therapeutics; MC2 01; MC2-01 (calcipotriol + BDP); MC2-14; PADcombo; PADscalp

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Drug Delivery Solutions ApS
  • Developer MC2 Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis
  • Discontinued Psoriasis

Most Recent Events

  • 30 Oct 2017 Chemical structure information added
  • 11 Oct 2017 Phase-III clinical trials in Plaque psoriasis in USA (Topical)
  • 11 Oct 2017 MC2 Therapeutics announces intention to submit NDA to US FDA for Plaque psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top